A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Efficacy Study of MK0928 15 mg and 10 mg in the Treatment of Adult Outpatients With Primary Insomnia

NCT00103818 Phase 3 COMPLETED

The purpose of this study is to evaluate the safety and effectiveness of MK0928 for insomnia (a sleep disorder).

Details

Lead sponsor	H. Lundbeck A/S
Phase	Phase 3
Status	COMPLETED
Enrolment	900
Start date	2005-02
Completion	2006-10

Conditions

• Insomnia

Interventions

• gaboxadol
• Comparator: placebo (unspecified)

Primary outcomes

• Patient-reported amount of sleep and time to fall asleep at night after 3 months — After 3 months